The art of SEN By Dr Joe Taylor

The £3.5bn special schools market is about to be transformed. But providers must ready themselves for the changes, argues Candesic's Dr Joe Taylor.

<< Back to Publications
    Page: Loading... / Loading...    
Download PDF


About

Candesic is a leading strategy consultancy head-quartered in London, serving private operators, investors, and public sector organisations.

Newsletter

Subscribe to our newsletter and stay up to date with the latest news.

News & Publications

ArchiMed acquires Eurolyser Diagnostica
[#Congratulations](https://www.linkedin.com/feed/hashtag/?keywords=%23Congratulations) to our client ArchiMed on their acquisition of Eurolyser Diagnostica, a fast- growing [#Austrian](https://www.linkedin.com/feed/hashtag/?keywords=%23Austrian) [#IVD](https://www.linkedin.com/feed/hashtag/?keywords=%23IVD) player. The announcement follows ArchiMed's investment in Italy-based DIESSE diagnostica senese SpA, and marks the fund's second investment in the IVD space this year. Eurolyser Diagnostica's [#pointofcare](https://www.linkedin.com/feed/hashtag/?keywords=%23pointofcare) platform serves three distinct end markets: [#medical](https://www.linkedin.com/feed/hashtag/?keywords=%23medical) diagnostics, [#veterinary](https://www.linkedin.com/feed/hashtag/?keywords=%23veterinary) diagnostics, and [#food](https://www.linkedin.com/feed/hashtag/?keywords=%23food) &amp; [#feed](https://www.linkedin.com/feed/hashtag/?keywords=%23feed). The business has grown from distinct leadership positions in both [hashtag#medical](https://www.linkedin.com/feed/hashtag/?keywords=%23medical) and [#veterinary](https://www.linkedin.com/feed/hashtag/?keywords=%23veterinary) mono tests, and it will be interesting to see how management is challenging the status quo of incumbents such as Orion Diagnostica Oy, IDEXX, and Abaxis, Inc.

Investing in Cancer Immunotherapy
Dr **Michelle Tempest** and Dr **Karen Sayal** reveal in this July 2019 **#LaingBuisson** article promising opportunities investing in **#immunotherapy** treatments

Candesic supports the $450m sale of Blue Earth Diagnostics to Bracco Group
Congratulations to Blue Earth Diagnostics' CEO [jonathan allis](https://www.linkedin.com/in/ACoAAAL4wkMB23NkTCX2n8urTX8E_6Pf32lQDdI/) and the management team on this $450M deal. Candesic is proud to have been part of this journey and looking forward to see the business grow under [#Bracco](https://www.linkedin.com/feed/hashtag/?keywords=%23Bracco)'s new ownership. Candesic provided vendor side due diligence to Blue earth diagnostics.

© Candesic 2016